Pharmya

  • Home
  • About us
  • Services
    • Pharmacovigilance Systems
    • Operational Pharmacovigilance Activities
    • EU QPPV & Local QPPV services
    • Pharmacovigilance Audits and Training
  • News
  • Careers
  • Contact us
  • English
  • Français
  • Español
You are here: Pharmya > All news > Authorisation for early access to medicines: HAS evaluation doctrine
France_acces_precoces_-_doctrine_27Apr2022-1Télécharger
Marie Berger 30 May 2022 All news
  • ← China : release of MedDRA Coding Guidance for Adverse DrugReaction (ADR) Reports
  • EU_EMA_PSUR eSubmission →

Pharmya – Pharmacovigilance

PHARMYA is a French based company, dedicated to providing Pharmacovigilance services. Its mission is to support the pharmaceutical industry, biotechnology companies, research centers and their service providers in their efforts to comply with international Pharmacovigilance regulations.

In partnership with the region

Contact

  • PHARMYA
  • 315 Av. Saint Sauveur du Pin
  • 34980 Saint Clément de Rivière (Montpellier), France
  • Phone: +33 411 93 21 10
  • Email: info@pharmya.com
  • Website: www.pharmya.com

News

  • The ANSM publishes its haemovigilance report for 2023
  • User’s booklet – ANSM
  • Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28-31 October 2024
Copyright © 2018 - Pharmya - Legal terms - Quality Policy